HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Winkelstein, J. A. Articles by Schiffman, G. Search for Related Content PubMed Articles by Winkelstein, J. A. Articles by Schiffman, G.

The Role of the Capsular Polysaccharide in the Activation of the Alternative Pathway by the Pneumococcus¹

From the Departments of Pediatrics and Microbiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, and the Department of Microbiology, The State University of New York Downstate Medical Center, Brooklyn, New York 11203

Abstract

Previous studies have shown that when pneumococci are incubated in normal, nonimmune serum, they activate the alternative pathway and opsonically active C3b is fixed to the surface of the organism. Other studies have demonstrated that C3-dependent opsonization via the alternative pathway plays a significant role in the nonimmune host's defense against the pneumococcus. The present studies concern the role of the capsular polysaccharide in initiating the activation of the alternative pathway by the pneumococcus.

Some pneumococcal capsular polysaccharide types, but not all, are able to activate the alternative pathway. Soluble purified capsular polysaccharide types 1, 4 and 25 activate the alternative pathway, whereas types 2, 3, 14, and 19 do not. Since the capsular polysaccharides exist in their native form attached to the pneumococcal surface, selected capsular polysaccharides were also tested for their ability to activate the alternative pathway when attached to a particulate carrier, sheep erythrocytes. Capsular polysaccharide types 2 and 3 failed to activate the alternative pathway when attached to sheep erythrocytes, paralleling the results obtained when these capsular polysaccharides were in solution. In contrast, the type 25 capsular polysaccharide not only activated the alternative pathway when attached to sheep erythrocytes, as it had when in solution, but is also initiated alternative pathway-mediated lysis of the erythrocytes.

The capsular polysaccharide is not required for the activation of the alternative pathway by the pneumococcus. Although all types of encapsulated pneumococci are able to activate the alternative pathway, not all the purified capsular polysaccharide types are able to do so. In addition, a nonencapsulated pneumococcus, derived originally from a type 2 organism, activates the alternative pathway as well as a fully encapsulated type 2 pneumococcus.

Footnotes

¹ This work was supported by United States Public Health Service Grants RO1-AI-11637, NO1-AI-42521, and 5-TO1-AI-00461.

² Jerry A. Winkelstein is an investigator of the Howard Hughes Medical Institute.

This article has been cited by other articles:

				C. E. Fasching, T. Grossman, B. Corthesy, A. G. Plaut, J. N. Weiser, and E. N. Janoff Impact of the Molecular Form of Immunoglobulin A on Functional Activity in Defense against Streptococcus pneumoniae Infect. Immun., April 1, 2007; 75(4): 1801 - 1810. [Abstract] [Full Text] [PDF]

				S. T. Test, J. K. Mitsuyoshi, and Y. Hu Depletion of Complement Has Distinct Effects on the Primary and Secondary Antibody Responses to a Conjugate of Pneumococcal Serotype 14 Capsular Polysaccharide and a T-Cell-Dependent Protein Carrier Infect. Immun., January 1, 2005; 73(1): 277 - 286. [Abstract] [Full Text] [PDF]

				S. T. Test, J. Mitsuyoshi, C. C. Connolly, and A. H. Lucas Increased Immunogenicity and Induction of Class Switching by Conjugation of Complement C3d to Pneumococcal Serotype 14 Capsular Polysaccharide Infect. Immun., May 1, 2001; 69(5): 3031 - 3040. [Abstract] [Full Text] [PDF]